Sequential Chemotherapies for Advanced Gastric Cancer: A Retrospective Analysis of 111 Patients

Elsing, Christoph; Herrmann, Christina; Hannig, Carla Verena; Stremmel, Wolfgang; Jäger, Dirk; Herrmann, Thomas
November 2013
Oncology;Nov2013, Vol. 85 Issue 5, p262
Academic Journal
Background: The role of second-line chemotherapy in advanced gastric cancer is not yet fully established. Patients and Methods: We analysed 111 patients with advanced gastric cancer treated at the University Hospital Heidelberg (51) and the private oncology practice Bottrop/Dorsten (60) between 2001 and 2011, comparing the outcome of patients with first-line chemotherapy and those who received second-line chemotherapy. Results: Thirty-six patients were treated with one chemotherapy regimen, 75 patients received at least two different chemotherapies. Patients who received one chemotherapy regimen were older (median age 69 years) and had a shorter overall survival (6 months) than patients receiving sequential chemotherapies [median age 61 years, p = 0.009, overall survival 14 months (2-42), p = 0.001]. Under second-line chemotherapy, partial response was observed in 25 patients (33%) and stable disease for ≥3 months in 26 patients (35%). Patients treated before 2005 had a slightly better overall survival than patients treated in or after 2005. Survival was not influenced by the treatment centre (primary or tertiary), but was influenced by former surgery. Conclusion: The prognosis of advanced gastric cancer is still poor. Selected patients may benefit from individualized salvage chemotherapy after failure of first-line chemotherapy. © 2013 S. Karger AG, Basel


Related Articles

  • Initially Localized Synovial Sarcoma in Adults: A Retrospective Single-Center Analysis of 26 Patients Registered at the Department of Oncology, University of Vienna between 2004 and 2013. Lamm, Wolfgang; Schur, Sophie; Köstler, Wolfgang J.; Amann, Gabriele; Pokrajac, Boris; Funovics, Philipp; Panotopoulos, Joannis; Brodowicz, Thomas // Oncology;Jul2014, Vol. 87 Issue 1, p48 

    Background: Synovial sarcoma is a rare subgroup of all soft-tissue sarcomas. The aim of this retrospective single-center analysis was to investigate the outcome of patients with initially localized disease. Patients and Methods: Twenty-six patients were enrolled in this retrospective...

  • Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis. Pink, Daniel; Richter, Stephan; Gerdes, Sebastian; Andreou, Dimosthenis; Tunn, Per-Ulf; Busemann, Christoph; Ehninger, Gerhard; Reichardt, Peter; Schuler, Markus K. // Oncology;Jul2014, Vol. 87 Issue 2, p95 

    Objective: Epithelioid sarcoma (ES) presents unique clinical features in comparison to other sarcoma subtypes. Data regarding the benefits of chemotherapy are very limited. Combination regimens using gemcitabine and docetaxel (Gem/Doce) have proven to be effective, especially in uterine and...

  • Comparison of the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer according to the Type of Epidermal Growth Factor Receptor Mutation. Igawa, Satoshi; Kasajima, Masashi; Ishihara, Mikiko; Kimura, Michiko; Hiyoshi, Yasuhiro; Asakuma, Maiko; Otani, Sakiko; Katono, Ken; Sasaki, Jiichiro; Masuda, Noriyuki // Oncology;Sep2014, Vol. 87 Issue 4, p215 

    Background: Exon 19 deletion and L858R point mutation of the epidermal growth factor receptor (EGFR) are the most commonly encountered EGFR mutations in non-small cell lung cancer (NSCLC), and predict higher clinical outcomes following treatment with gefitinib. The objective of this study was to...

  • O-MAX Chemotherapy: High Activity in Metastatic Esophagogastric Adenocarcinoma and Possible Relation to Subclinical Hemolysis. Ahlgren, James; Patel, Nihar; Simmens, Samuel; Akin, Esma; Bishop, Catherine; Kirkel, Dean; Siegel, Paula; Schuck, Suzanne; Guebre-Xabiher, Hiwot; Siegel, Robert // Oncology;Nov2014, Vol. 87 Issue 6, p371 

    Objectives: Our objectives were to confirm the activity of O-MAX chemotherapy in adenocarcinoma of the stomach and esophagus, particularly the high rate of complete remission (CR) and the relation of subclinical hemolysis to CR. Patients and Methods: Twenty-five patients with metastatic...

  • Cutaneous versus Non-Cutaneous Angiosarcoma: Clinicopathologic Features and Treatment Outcomes in 60 Patients at a Single Asian Cancer Centre. Farid, Mohamad; Ong, Whee Sze; Lee, Marcus Jin Fu; Jeevan, Raaj; Ho, Zhen Chong; Sairi, Alisa Noor Hidayah; Soh, Lay Tin; Poon, Donald; Teh, Jonathan; Chin, Francis; Teo, Melissa; Quek, Richard // Oncology;Oct2013, Vol. 85 Issue 3, p182 

    Background: Angiosarcoma (AS) is an uncommon soft tissue sarcoma with dismal prognosis that presents either cutaneously (C-AS) or non-cutaneously (NC-AS). We compared the clinical features and treatment outcomes between these 2 groups. Methods: A single-centre study evaluating 60 AS patients...

  • Radiation Therapy for Chemotherapy-Resistant Recurrent Epithelial Ovarian Cancer. Machida, Shizuo; Takei, Yuji; Yoshida, Chikako; Takahashi, Yoshifumi; Koyanagi, Takahiro; Sato, Naoto; Taneichi, Akiyo; Saga, Yasushi; Fujiwara, Hiroyuki; Suzuki, Mitsuaki // Oncology;Jun2014, Vol. 86 Issue 4, p232 

    Objectives: While radiation therapy is administered as a palliative treatment for recurrent ovarian cancer, it remains unclear whether it improves the prognosis. Methods: The effects and adverse events of radiation therapy for patients with recurrent epithelial ovarian cancer were investigated...

  • Validation of the Criteria of Transcatheter Arterial Chemoembolization Failure or Refractoriness in Patients with Advanced Hepatocellular Carcinoma Proposed by the LCSGJ. Arizumi, Tadaaki; Ueshima, Kazuomi; Chishina, Hirokazu; Kono, Masashi; Takita, Masahiro; Kitai, Satoshi; Inoue, Tatsuo; Yada, Norihisa; Hagiwara, Satoru; Minami, Yasunori; Sakurai, Toshiharu; Nishida, Naoshi; Kudo, Masatoshi // Oncology;Nov2014 Supplement, Vol. 87, p32 

    Background: Transcatheter arterial chemoembolization (TACE) failure or refractoriness is an indication for sorafenib therapy in patients with advanced hepatocellular carcinoma. The study evaluated the validity of the definition of TACE failure or refractoriness as proposed by the Liver Cancer...

  • Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma. D'angelo, Sandra P.; Munhoz, Rodrigo R.; Kuk, Deborah; Landa, Johnathan; Hartley, Eliza W.; Bonafede, Michael; Dickson, Mark a.; Gounder, Mrinal; Keohan, Mary L.; Crago, aimee M.; antonescu, Cristina R.; Tap, William D. // Oncology;Sep2015, Vol. 89 Issue 4, p205 

    Background: Angiosarcomas (AS) are rare tumors of vascular origin with a variable behavior and overall poor prognosis. We sought to assess the outcomes of patients treated for metastatic disease. Methods: We performed a retrospective analysis of 119 patients treated for metastatic AS. Outcomes...

  • Pharmacoeconomic Implications of Lenalidomide Maintenance Therapy in Multiple Myeloma. Kim, Miriam Y.; Sposto, Richard; Swaika, Abhisek; Asano, Hitomi; Alamgir, Ahsan; Chanan-Khan, Asher; Ailawadhi, Sikander // Oncology;Sep2014, Vol. 87 Issue 4, p224 

    We compared the three arms of the MM-015 randomized phase III clinical trial [melphalan and prednisone (MP), MP plus lenalidomide (MPR), and MPR plus lenalidomide maintenance (MPR-R)] to determine whether the addition of lenalidomide maintenance therapy for primary treatment of multiple myeloma...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics